Skip to main content

Table 2 Relationship between age and level of total IgG, IgG subclasses, and IgM responses to MSP3, MSP1-19, and GLURP

From: Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso

Antigens Age groups (in years) N GM*IgG(95%CI) GM*IgG1(95%CI) GM*IgG2(95%CI) GM*IgG3(95%CI) GM*IgG4(95%CI) GM*IgGM(95%CI)
MSP3 [0.5-3] 79 2.96 (2.88-3.04) 0.18 (0.14-0.23) 0.23 (0.21-0.24) 0.29 (0.22-0.37) 0.05 (0.04-0.06) 1.16 (1.06-1.28)
  ] 3-5] 69 3.22 (3.13-3.31) 0.24 (0.19-0.31) 0.22 (0.19-0.26) 0.49 (0.38-0.64) 0.05 (0.04-0.06) 0.99 (0.88-1.18)
  ] 5-10] 84 3.35 (3.25-3.45) 0.41 (0.33-0.52) 0.28 (0.25-0.30) 0.71 (0.56-0.92) 0.06 (0.05-0.07) 1.21 (1.06-1.39)
  > 10 21 3.51 (3.30-3.70) 0.69 (0.40-1.21) 0.35 (0.26-0.47) 1.05 (0.63-1.75) 0.14 (0.03-0.54) 1.39 (1.12-1.73)
  P   0,01 0,01 0,01 0,01 0,002 0,10
MSP1-19 ] 0.5-3] 79 3.13 (0.99-3.28) 1.19 (0.97-1.45) 0.21 (0.18-0.23) 0.40 (0.33-0.48) 0.02 (0.01-0.03) 0.86 (0.77-0.96)
  ] 3-5] 69 3.07 (2.95-3.19) 0.97 (0.80-1.17 0.26 (0.24-0.29) 0.48 (0.40-0.57) 0.03 (0.02-0.05) 1.22 (1.11-1.35)
  ] 5-10] 84 3.21 (3.07-3.34) 1.02 (0.86-1.21) 0.30 (0.27-0.34) 0.64 (0.54-0.75) 0,03 (0,03-0,09) 1.41 (1.29-1.54)
  > 10 21 3.09 (2.89-3.31) 1.33 (0.96-1.86) 0.35 (0.27-0.45) 0.52 (0.37-0.74) 0.03 (0.02-0.05) 0.98 (0.77-1.25)
  P   0,072 0.01 0.001 0.001 0.09 0.01
GLURP ] 0.5-3] 79 3.13 (3.02-3.25) 0.62 (0.51-0.76) 0.29 (0.26-0.32) 0.44 (0.38-0.50) 0.03 (0.01-0.06) 0.54 (0.45-0.65)
  ] 3-5] 69 3.41 (3.28-3.55) 0.77 (0.63-0.94) 0.36 (0.32-0.41) 0.55 (0.48-0.63) 0.01 (0.01-0.02) 0.80 (0.72-0.88)
  ] 5-10] 84 3.68 (3.53-3.84) 0.84 (0.69-1.09) 0.51 (0.43-0.61) 0.60 (0.52-0.68) 0.05 (0.02-0.09) 0.95 (0.84-1.09)
  > 10 21 3.89 (3.58-4.22) 1.35 (0.96-1.88) 0.64 (0.51-0.82) 0.88 (0.66-1.17) 0.05 (0.02-0.09) 2.00 (1.47-2.73)
  P   0.01 0.01 0.01 0.01 0.056 0.01
  1. N: number of children, GM*: geometric mean of Ig
Back to article page